Phenotypes associated with this allele

• Allele Symbol: Fpr2^tm1.2Jimw
• Allele Name: targeted mutation 1.2, Ji Ming Wang
• Allele ID: MGI:4459725
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Fpr2^tm1.2Jimw/Fpr2^tm1.2Jimw	B6.129X1-Fpr2^tm1.2Jimw	MGI:4459806
hm2	Fpr2^tm1.2Jimw/Fpr2^tm1.2Jimw	involves: 129X1/SvJ	MGI:5503978

Genotype
MGI:4459806

hm1

• Allelic Composition: Fpr2^tm1.2Jimw/Fpr2^tm1.2Jimw
• Genetic Background: B6.129X1-Fpr2^tm1.2Jimw

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

decreased dendritic cell number ( J:160074 )

• ovalbumin-treated mice exhibit decreased CD11c+ dencritic cells into the T cell zone of lymph nodes compared with similarly treated wild-type mice

decreased immunoglobulin level ( J:160074 )

• ovalbumin-treated mice exhibit reduced serum levels of type 2 immunoglobulin, IgE, ovalbumin-specific IgE, IgG1, and IgG2b compared with similarly treated wild-type mice

• ovalbumin-treated mice exhibit reduced secondary reduction of anti-ovalbumin IgG1 and IgG2b compared with similarly treated wild-type mice

decreased IgE level ( J:160074 )

• in ovalbumin-treated mice

decreased IgG1 level ( J:160074 )

• in ovalbumin-treated mice

decreased IgG2b level ( J:160074 )

• in ovalbumin-treated mice

small lymph nodes ( J:160074 )

• ovalbumin-treated mice exhibit reduced size of mediastinal draining lymph nodes and T/B lymphocyte zones compared with similarly treated wild-type mice

abnormal dendritic cell physiology ( J:160074 )

• ovalbumin-treated mice exhibit decreased recruitment of CD11c+ dendritic cells into the bronchial epithelial layer and dendritic cell exudation into bronchoalveolar fluid compared with similarly treated wild-type mice

abnormal cytokine secretion ( J:160074 )

• ovalbumin-treated mice produce less type 2 cytokine than similarly treated wild-type mice

• however, ovalbumin-treated mice exhibit normal production of type 1 cytokine interferon-gamma

decreased interferon-gamma secretion ( J:160074 )

• in LPS and ovalbumin-treated mice

decreased interleukin-13 secretion ( J:160074 )

• splenocytes from ovalbumin-treated mice

decreased interleukin-2 secretion ( J:160074 )

• in LPS and ovalbumin-treated mice

decreased interleukin-4 secretion ( J:160074 )

• splenocytes from ovalbumin-treated mice

decreased interleukin-5 secretion ( J:160074 )

• splenocytes from ovalbumin-treated mice

decreased inflammatory response ( J:160074 )

• ovalbumin-treated mice exhibit reduced inflammation with reduced infiltration of inflammatory cells compared with similarly treated wild-type mice

• ovalbumin-treated mice exhibit decreased recruitment of CD11c+ dendritic cells into the bronchial epithelial layer and dendritic cell exudation into bronchoalveolar fluid compared with similarly treated wild-type mice

• ovalbumin-treated mice exhibit reduced size of mediastinal draining lymph nodes and T/B lymphocyte zones compared with similarly treated wild-type mice

• ovalbumin-treated mice exhibit decreased CD11c+ dencritic cells into the T cell zone of lymph nodes compared with similarly treated wild-type mice

• thioglycollate and casein-treated mice exhibit reduced myeloid cell exudation into the peritoneal cavity compared with similarly treated wild-type mice

• LPS and ovalbumin-treated mice exhibit reduced neutrophil exudation into the bronchoalveolar liquid and infiltration in the lung with reduced production of interferon-gamma and IL2 compared with wild-type mice

• untreated and ovalbumin-treated mice exhibit reduced goblet cells in the lung compared with wild-type mice

• however, transfer of wild-type cells exposed to ovalbumin restores ovalbumin response

abnormal innate immunity ( J:160074 )

impaired macrophage chemotaxis ( J:160074 )

• in response to MMK-1

impaired neutrophil chemotaxis ( J:160074 )

• in response to MMK-1

respiratory system

decreased respiratory mucosa goblet cell number ( J:160074 )

• untreated and ovalbumin-treated mice exhibit reduced goblet cells in the lung compared with wild-type mice

hematopoietic system

impaired macrophage chemotaxis ( J:160074 )

• in response to MMK-1

impaired neutrophil chemotaxis ( J:160074 )

• in response to MMK-1

decreased dendritic cell number ( J:160074 )

• ovalbumin-treated mice exhibit decreased CD11c+ dencritic cells into the T cell zone of lymph nodes compared with similarly treated wild-type mice

decreased immunoglobulin level ( J:160074 )

• ovalbumin-treated mice exhibit reduced serum levels of type 2 immunoglobulin, IgE, ovalbumin-specific IgE, IgG1, and IgG2b compared with similarly treated wild-type mice

• ovalbumin-treated mice exhibit reduced secondary reduction of anti-ovalbumin IgG1 and IgG2b compared with similarly treated wild-type mice

decreased IgE level ( J:160074 )

• in ovalbumin-treated mice

decreased IgG1 level ( J:160074 )

• in ovalbumin-treated mice

decreased IgG2b level ( J:160074 )

• in ovalbumin-treated mice

abnormal bone marrow cell physiology ( J:160074 )

• MMK-1-treated bone marrow cells fail to migrate and fMLP-treated cells exhibit reduced response compared with similarly treated wild-type cells

cellular

impaired macrophage chemotaxis ( J:160074 )

• in response to MMK-1

impaired neutrophil chemotaxis ( J:160074 )

• in response to MMK-1

Genotype
MGI:5503978

hm2

• Allelic Composition: Fpr2^tm1.2Jimw/Fpr2^tm1.2Jimw
• Genetic Background: involves: 129X1/SvJ

Reduced length of colonic crypts in Fpr2^tm1.2Jimw/Fpr2^tm1.2Jimw and Del(17Fpr1-Fpr2)1Jimw/Del(17Fpr1-Fpr2)1Jimw mice

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:197568 )

• 14 days after DSS treatment

digestive/alimentary system

abnormal enterocyte proliferation ( J:197568 )

• reduced proliferation of epithelial cells in colonic crypts of untreated mice

• reduced proliferation of colonic epithelial cells in mice treated with DSS at day 4 and 8

abnormal large intestine crypts of Lieberkuhn morphology ( J:197568 )

• shorter than normal colonic crypts in untreated and DSS-treated mice

intestinal ulcer ( J:197568 )

• colonic ulcers in DSS-treated mice

abnormal colon morphology ( J:197568 )

• thickened muscularis propria in DSS-treated mice

• reduced colon length in DSS-treated mice

increased colon adenoma incidence ( J:197568 )

• in mice treated with AOM and DSS

colitis ( J:197568 )

• mice exposed to DSS exhibit reduced early rectal bleeding, weight loss, leukocyte recruitment and colon disease scores but reduced recovery following DSS withdrawal disease symptoms worsen and die by day 14 compared with wild-type mice

neoplasm

increased colon adenoma incidence ( J:197568 )

• in mice treated with AOM and DSS

increased incidence of tumors by chemical induction ( J:197568 )

• mice treated with AOM and DSS develop colonic adenoma, hyperplastic polyps and serrated adenomas with a higher rate of malignant transformation compared with wild-type mice

cellular

abnormal dendritic cell chemotaxis ( J:199611 )

• impaired in response to bronchoalveolar lavage fluid from inflamed lungs

abnormal enterocyte proliferation ( J:197568 )

• reduced proliferation of epithelial cells in colonic crypts of untreated mice

• reduced proliferation of colonic epithelial cells in mice treated with DSS at day 4 and 8

endocrine/exocrine glands

abnormal large intestine crypts of Lieberkuhn morphology ( J:197568 )

• shorter than normal colonic crypts in untreated and DSS-treated mice

homeostasis/metabolism

increased susceptibility to xenobiotic induced morbidity/mortality ( J:197568 )

• 14 days after DSS treatment

increased incidence of tumors by chemical induction ( J:197568 )

• mice treated with AOM and DSS develop colonic adenoma, hyperplastic polyps and serrated adenomas with a higher rate of malignant transformation compared with wild-type mice

immune system

colitis ( J:197568 )

• mice exposed to DSS exhibit reduced early rectal bleeding, weight loss, leukocyte recruitment and colon disease scores but reduced recovery following DSS withdrawal disease symptoms worsen and die by day 14 compared with wild-type mice

decreased dendritic cell number ( J:199611 )

• of inflammatory dendritic cells in inflamed airways in response to inhaled ovalbumin combined with a low dose of LPS

abnormal dendritic cell physiology ( J:199611 )

• reduced recruitment of monocyte-derived inflammatory dendritic cells into inflamed airways in response to inhaled ovalbumin combined with a low dose of LPS

• reduced infiltration of inflammatory dendritic cells into the peribronchiole region

• however, adoptive transfer of wild-type mouse bone marrow cells restores trafficking of inflammatory dendritic cells

abnormal dendritic cell chemotaxis ( J:199611 )

• impaired in response to bronchoalveolar lavage fluid from inflamed lungs

decreased acute inflammation ( J:197568 )

• in the colon of DSS-treated mice

hematopoietic system

abnormal dendritic cell chemotaxis ( J:199611 )

• impaired in response to bronchoalveolar lavage fluid from inflamed lungs

decreased dendritic cell number ( J:199611 )

• of inflammatory dendritic cells in inflamed airways in response to inhaled ovalbumin combined with a low dose of LPS